See more : Nickel Rock Resources Inc. (NICL.V) Income Statement Analysis – Financial Results
Complete financial analysis of Therma Bright Inc. (TBRIF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Therma Bright Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Eline Entertainment Group, Inc. (EEGI) Income Statement Analysis – Financial Results
- Sino American Oil Company (OILY) Income Statement Analysis – Financial Results
- Henan Pinggao Electric Co.,Ltd. (600312.SS) Income Statement Analysis – Financial Results
- Aiphone Co.,Ltd. (6718.T) Income Statement Analysis – Financial Results
- Banque Cantonale Vaudoise (BCVN.SW) Income Statement Analysis – Financial Results
Therma Bright Inc. (TBRIF)
About Therma Bright Inc.
Therma Bright Inc. engages in the development and sale of rapid COVID testing products, medical devices for pain management, devices to improve circulation, and devices for the cosmeceutical industry. The company's products include AcuVid, an antigen and antibody rapid screening test for COVID-19; InterceptCS, a cold sore prevention system, which provides controlled topical heat without the risk of burning the skin; Benepod, a hot and cold contrast therapy device for pain relief without pain relieving medication; Venowave, a medical compression pump designed to treat and alleviate the symptoms associated with poor circulation; and TherOZap, a thermal therapy insect device that reduces the inflammatory response, as well as relieves the symptoms of pain, itching, and inflammation associated with insect bites and stings. It serves consumers and medical professionals. The company was formerly known as The Jenex Corporation and changed its name to Therma Bright Inc. in February 2018. Therma Bright Inc. was incorporated in 2001 and is based in Toronto, Canada.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 26.07K | 23.90K | 139.43K | 3.88K | 3.78K | 6.91K | 14.10K | 31.16K | 4.79K | 1.71K | 0.00 | 0.00 | 0.00 | 0.00 | 172.75K | 251.02K | 250.86K | 770.03K | 43.81K | 38.54K | 37.83K | 6.50K |
| Cost of Revenue | 614.00 | 0.00 | 75.95K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 439.00 | 0.00 | 0.00 | 0.00 | 0.00 | 141.00K | 372.71K | 121.96K | 281.02K | 27.43K | 24.08K | 23.72K | 0.00 |
| Gross Profit | 25.46K | 23.90K | 63.48K | 3.88K | 3.78K | 6.91K | 14.10K | 31.16K | 4.79K | 1.27K | 0.00 | 0.00 | 0.00 | 0.00 | 31.75K | -121.69K | 128.90K | 489.01K | 16.38K | 14.45K | 14.11K | 6.50K |
| Gross Profit Ratio | 97.64% | 100.00% | 45.53% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 74.31% | 0.00% | 0.00% | 0.00% | 0.00% | 18.38% | -48.48% | 51.38% | 63.50% | 37.38% | 37.50% | 37.30% | 100.00% |
| Research & Development | 9.69K | 446.58K | 805.54K | 1.37M | 13.08K | 60.67K | 92.49K | 97.81K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 570.00 | 9.05K | 58.65K | 0.00 | 0.00 |
| General & Administrative | 1.15M | 3.18M | 4.94M | 7.17M | 597.83K | 346.27K | 1.16M | 898.70K | 210.34K | 351.86K | 440.91K | 317.77K | 0.00 | 0.00 | 756.94K | 0.00 | 0.00 | 0.00 | 0.00 | 704.05K | 706.22K | 26.73K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 68.35K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 343.04K | 0.00 | 0.00 | 0.00 | 0.00 | 2.12K | 23.22K | 115.00 |
| SG&A | 1.15M | 3.18M | 4.94M | 7.17M | 597.83K | 346.27K | 1.16M | 898.70K | 210.34K | 351.86K | 440.91K | 317.77K | 262.41K | 193.63K | 1.10M | 1.30M | 1.22M | 1.96M | 1.15M | 706.17K | 729.44K | 26.84K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.15M | 1.75M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 1.16M | 3.63M | 5.90M | 8.60M | 613.89K | 409.73K | 1.25M | 996.51K | 210.34K | 351.86K | 440.91K | 317.77K | 262.41K | 193.63K | 1.11M | 1.32M | 1.31M | 2.10M | 1.18M | 713.41K | 931.71K | 28.10K |
| Cost & Expenses | 1.16M | 3.63M | 5.98M | 8.60M | 613.89K | 409.73K | 1.25M | 996.51K | 210.34K | 352.30K | 440.91K | 317.77K | 262.41K | 193.63K | 1.25M | 1.70M | 1.43M | 2.38M | 1.21M | 737.49K | 955.43K | 28.10K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.06K | 0.00 | 0.00 |
| Interest Expense | 8.60K | 13.44K | 1.38K | 0.00 | 17.40K | 18.91K | 8.74K | 0.00 | 0.00 | 3.90K | 643.97K | 550.99K | 473.02K | 423.68K | 312.72K | 267.74K | 0.00 | 0.00 | 0.00 | 1.27K | 0.00 | 0.00 |
| Depreciation & Amortization | 99.51K | 75.38K | 53.85K | 57.98K | 2.98K | 2.79K | 76.00 | 247.00 | 22.82K | 3.90K | 1.80M | 2.30M | 473.02K | 423.68K | 8.89K | 20.34K | 97.21K | 136.62K | 35.73K | 21.00K | 202.27K | 163.63K |
| EBITDA | -2.34M | -3.68M | -5.73M | -8.55M | -606.31K | -400.24K | -1.24M | -965.10K | -205.55K | -350.59K | 710.24K | 1.43M | -262.41K | -193.63K | -1.07M | -1.82M | -1.09M | -1.47M | -1.13M | -1.35M | -466.92K | -715.33K |
| EBITDA Ratio | -8,988.07% | -15,393.76% | -4,077.18% | -219,824.44% | -16,048.82% | -5,793.37% | -8,768.46% | -3,096.93% | -4,288.52% | -20,514.16% | 0.00% | 0.00% | 0.00% | 0.00% | -618.36% | -567.40% | -433.19% | -190.85% | -2,582.01% | -1,759.32% | -1,890.80% | 2,184.40% |
| Operating Income | -1.14M | -3.60M | -5.68M | -8.54M | -607.13K | -400.03K | -1.24M | -965.34K | -205.55K | -354.49K | -1.08M | -868.76K | -735.43K | -617.31K | -1.09M | -1.44M | -1.18M | -1.61M | -1.17M | -698.95K | -917.60K | -21.60K |
| Operating Income Ratio | -4,355.04% | -15,076.51% | -4,077.18% | -219,824.44% | -16,048.82% | -5,793.37% | -8,769.00% | -3,097.72% | -4,288.52% | -20,742.36% | 0.00% | 0.00% | 0.00% | 0.00% | -633.18% | -575.50% | -471.94% | -208.59% | -2,663.56% | -1,813.82% | -2,425.45% | -332.17% |
| Total Other Income/Expenses | -1.32M | -164.64K | -196.39K | -74.54K | -19.56K | -21.90K | -8.81K | -247.00 | -472.00 | -1.88K | 1.15M | 1.73M | -41.06K | 0.00 | -420.04K | -390.97K | -228.63K | -95.70K | 17.40K | -589.48K | 3.76K | -42.30K |
| Income Before Tax | -2.45M | -3.77M | -5.88M | -8.61M | -626.68K | -421.93K | -1.24M | -965.59K | -206.02K | -356.37K | 68.21K | 860.04K | -735.43K | -617.31K | -1.51M | -1.84M | -1.41M | -1.70M | -1.15M | -1.96M | -959.90K | -21.65K |
| Income Before Tax Ratio | -9,402.79% | -15,765.40% | -4,218.03% | -221,744.06% | -16,565.74% | -6,110.51% | -8,769.54% | -3,098.51% | -4,298.37% | -20,852.60% | 0.00% | 0.00% | 0.00% | 0.00% | -876.33% | -731.25% | -563.07% | -221.02% | -2,623.86% | -5,079.90% | -2,537.27% | -332.93% |
| Income Tax Expense | 0.00 | 0.00 | 1.38K | -178.58K | 17.40K | 18.91K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 312.72K | 267.74K | 195.65K | 133.18K | 20.67K | 361.30K | -295.99K | -9.50K |
| Net Income | -2.45M | -3.77M | -5.88M | -8.61M | -626.68K | -421.93K | -1.24M | -965.59K | -206.02K | -356.37K | 68.21K | 860.04K | -735.43K | -617.31K | -1.51M | -2.10M | -1.61M | -1.84M | -1.15M | -2.32M | -663.91K | -12.15K |
| Net Income Ratio | -9,402.79% | -15,765.40% | -4,218.03% | -221,744.06% | -16,565.74% | -6,110.51% | -8,769.54% | -3,098.51% | -4,298.37% | -20,852.60% | 0.00% | 0.00% | 0.00% | 0.00% | -876.33% | -837.92% | -641.07% | -238.31% | -2,623.86% | -6,017.49% | -1,754.88% | -186.82% |
| EPS | -0.01 | -0.02 | -0.03 | -0.04 | 0.00 | 0.00 | -0.01 | -0.01 | 0.00 | 0.00 | 0.01 | 0.01 | -0.01 | -0.01 | -0.03 | -0.04 | -0.03 | -0.04 | -0.03 | -0.06 | -0.02 | 0.00 |
| EPS Diluted | -0.01 | -0.02 | -0.03 | -0.04 | 0.00 | 0.00 | -0.01 | -0.01 | 0.00 | 0.00 | 0.01 | 0.01 | -0.01 | -0.01 | -0.03 | -0.04 | -0.03 | -0.04 | -0.03 | -0.06 | -0.02 | 0.00 |
| Weighted Avg Shares Out | 315.92M | 242.84M | 228.45M | 199.96M | 163.80M | 163.27M | 148.52M | 116.63M | 110.35M | 88.46M | 78.09M | 69.12M | 66.78M | 66.78M | 55.93M | 52.28M | 49.17M | 44.68M | 40.80M | 39.76M | 32.58M | 20.05M |
| Weighted Avg Shares Out (Dil) | 315.92M | 242.84M | 228.45M | 199.96M | 163.80M | 163.27M | 148.52M | 116.63M | 110.35M | 88.46M | 78.09M | 69.12M | 66.78M | 66.78M | 55.93M | 52.28M | 49.17M | 44.68M | 40.80M | 39.76M | 32.58M | 20.05M |
Therma Bright Announces Venowave Pilot Tests with Existing and New Distribution Partners in the United States
Toronto, Ontario--(Newsfile Corp. - November 2, 2023) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX) ("Therma" or the "Company"), developer and partner in a wide-range of leading-edge, proprietary diagnostic and medical device technologies, announced today the Company has...
Therma Bright appoints Eric Myung as new CEO
Therma Bright Inc (TSX-V:THRM, OTC:TBRIF) told investors that Eric Myung has assumed the role of the company's new chief financial officer (CFO) with immediate effect. He succeeds Victor Hugo, who served as CFO since July 2018.
Therma Bright Announces New CFO
Toronto, Ontario--(Newsfile Corp. - September 29, 2023) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer and partner in a wide-range of leading-edge, proprietary diagnostic and medical device technologies, is pleased to announce that Mr. Eric...
Therma Bright Announces Change of Auditor
Toronto, Ontario--(Newsfile Corp. - September 29, 2023) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer and partner in a wide-range of leading-edge, proprietary diagnostic and medical device technologies, announces that it has changed its auditors...
Therma Bright Announces Amendments to InStatin & InVixa Acquisitions
InStatin & InVixa Are Developing Novel Treatments for COVID-19, Asthma, and Chronic Obstructive Pulmonary Disease (COPD) Toronto, Ontario--(Newsfile Corp. - September 27, 2023) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer of its smart-enabled AcuVid™...
Therma Bright Adds Hero LifeCare as Northeast Venowave Distribution Partner
Toronto, Ontario--(Newsfile Corp. - September 13, 2023) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer and partner in a wide-range of leading-edge, proprietary diagnostic and medical device technologies, announced today the Company has signed Hero...
Therma Bright Submits Updated FDA 510K Application Requesting Correction of Venowave Device's Intended Use, Labeling, and Description
Toronto, Ontario--(Newsfile Corp. - September 7, 2023) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer and partner in a wide-range of leading-edge, proprietary diagnostic and medical device technologies, announced today the Company has submitted an...
Therma Bright Provides Update on Venowave's Permanent CPT/HCPCS Code Application Process
Toronto, Ontario--(Newsfile Corp. - August 22, 2023) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer and partner in a wide-range of leading-edge, proprietary diagnostic and medical device technologies, announced today that the Company has heard...
Therma Bright says permanent insurance codes for Venowave expected over coming weeks
Therma Bright Inc (TSX-V:THRM, OTC:TBRIF) said that in the coming weeks, it expects a final decision on permanent codes from the Centers for Medicare and Medicaid Services (CMS) for Venowave, its compact, lightweight deep vein thrombosis (DVT) prevention device. The company...
Therma Bright Provides Update on Venowave's Permanent CPT/HCPCS Codes and United States Distribution Partners
Toronto, Ontario--(Newsfile Corp. - August 4, 2023) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), developer and partner in a wide-range of leading-edge, proprietary diagnostic and medical device technologies, announced today that it expects a final...
Source: https://incomestatements.info
Category: Stock Reports